Table 3.

Clinical measures after randomization in participants assigned to receive dietary potassium restriction or standard care

VariablesControlPotassium RestrictionP Value
Change in eGFR,a ml/min per 1.73 m2−5.4±8.5−5.2±7.90.91
Final eGFR, ml/min per 1.73 m231±1128±110.94
Change in systolic BP,a mmHg2±17−5±180.25
Change in weight,a kg−1.8±3.8−1.1±6.00.65
Received sodium polystyrene sulfonate, n/N (%)2/21 (9.5)10/21 (47.6)0.02
Time on sodium polystyrene sulfonate,b mo1.5±0.719.5±5.4
Sodium polystyrene sulfonate dose,b g/d11.3±5.319.8±7.8
Potassium data
 Mean serum potassium,c mEq/L4.8±0.44.6±0.50.03
 Change in serum potassium,a mEq/L0.1±0.7−0.1±0.80.40
 Serum potassiumd <4.5 mEq/L n/N (%)14/76 (21)32/65 (42)0.002
 Change in 24-h urinary potassium,a mEq/24 h2.3 (−46–65)−7.9 (−40–29)0.24
Dietary nutrient data
 Mean dietary potassium,c,e mg/d3874 (2769–4812)3272 (2524–3954)0.001
 Change in dietary potassium,a,e mg/d−343 (−999–153)−854 (−1606–0)0.35
 Change in dietary sodium,a mg/d−115.6±1444.6−768.3±1426.50.15
 Change in protein,a mg/d−17.3±41.0−11.4±30.60.60
 Change in energy,a kJ/d1230±38591506±34420.81
  • Continuous variables are summarized as mean±SD.

  • a Change refers to analysis of the change from baseline to final value.

  • b Average months and dose of sodium polystyrene sulfonate among participants who received the drug (n=2 control; n=10 intervention).

  • c Group mean data were assessed at 6-month intervals and are expressed as raw unadjusted means, with P values from generalized linear model analyses adjusted for baseline value.

  • d Proportions are over postrandomization visits assessed at 6-month intervals. P values are from a generalized linear model adjusting for baseline and account for the correlation within a patient over time.

  • e Indicates variables that are not normally distributed and are summarized as median (interquartile range).